Steve Davis, CEO

40th Annual J.P. Morgan Healthcare Conference

January 11, 2022

Forward-Looking Statements

This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed in or implied by such forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about (i) plans for, including timing and progress of commercialization of, NUPLAZID® or for the clinical development of our product candidates, including pimavanserin and trofinetide; (ii) benefits to be derived from and efficacy of our product candidates, including the use of pimavanserin in dementia-related psychosis, schizophrenia or other neurological or psychiatric indications, potential advantages of NUPLAZID versus existing antipsychotics or antidepressants, and expansion opportunities for NUPLAZID; (iii) estimates regarding the prevalence of Parkinson's disease psychosis, dementia-related psychosis, schizophrenia and the potential use of trofinetide in Rett syndrome; (iv) potential markets for any of our products, including NUPLAZID and trofinetide; (v) our estimates regarding our future financial performance, cash position or capital requirements; and (vi) currently anticipated impacts of COVID-19 on Acadia's business, including its commercial sales operations, current and planned clinical trials, supply chain, and guidance for full-year 2021 NUPLAZID net sales and certain expense line items.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of the risks and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2020 as well as our subsequent filings with the SEC. The forward- looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them for future events.

Provided January 11, 2022 as part of an oral presentation and is qualified by such; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.

2

Elevate Life

3

Acadia's Growth Strategy

Drive Growth of

2 Submissions

Develop the Next Wave

NUPLAZID® Franchise

to FDA in 2022

of Breakthroughs

• Complete pimavanserin ADVANCE-2

• Bottle and share growth in FY21

• Resubmit pimavanserin sNDA for

Phase 3 study in NSS (Results in 2023)

despite ongoing pandemic headwinds

Alzheimer's Diseases Psychosis

(ADP) in 1Q22

• Announce results from two ACP-044

Phase 2 studies in models of

• Continue strong relative performance

acute (~1Q22) & chronic pain (4Q22)

compared to PD market and

• Submit trofinetide NDA for

other branded LTC medications

Rett syndrome in

• Continue Phase 1 for ACP-319

mid-2022

• Execute strategic BD opportunities

Building a Leading CNS Company

NSS = Negative Symptoms of Schizophrenia.

NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.4 Provided January 11, 2022 as part of an oral presentation and is qualified by such; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.

Drive Growth of NUPLAZID® Franchise

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

ACADIA Pharmaceuticals Inc. published this content on 11 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2022 15:37:04 UTC.